Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.
Piñana JL, Vázquez L, Martino R, de la Cámara R, Sureda A, Rodríguez-Veiga R, Garrido A, Sierra J, Ribera JM, Torrent A, Mateos MV, de la Rubia J, Tormo M, Díez-Campelo M, García-Gutiérrez V, Álvarez-Larrán A, Sancho JM, MartínGarcía-Sancho A, Yañez L, Pérez Simón JA, Barba P, Abrisqueta P, Álvarez-Twose I, Bonanad S, Lecumberri R, Ruiz-Camps I, Navarro D, Hernández-Rivas JÁ, Cedillo Á, García-Sanz R, Bosch F. Piñana JL, et al. Leuk Lymphoma. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. Epub 2021 Oct 20. Leuk Lymphoma. 2022. PMID: 34668835 Free PMC article.
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups. Martínez-Cuadrón D, et al. Ann Hematol. 2018 May;97(5):763-772. doi: 10.1007/s00277-018-3229-5. Epub 2018 Feb 2. Ann Hematol. 2018. PMID: 29392425 Clinical Trial.
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups. Martínez-Cuadrón D, et al. Ann Hematol. 2018 May;97(5):923. doi: 10.1007/s00277-018-3277-x. Ann Hematol. 2018. PMID: 29473097 Free article.
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R, Montesinos P, Boluda B, Lorenzo I, Martínez-Cuadrón D, Salavert M, Pemán J, Calvillo P, Cano I, Acuña E, Villalba A, Piñana JL, Sanz J, Solves P, Senent L, Vicente A, Sempere A, Cervera J, Barragán E, Jarque I, Torres A, Sanz MA, Sanz GF. Rodríguez-Veiga R, et al. Ann Hematol. 2019 Sep;98(9):2081-2088. doi: 10.1007/s00277-019-03744-5. Epub 2019 Jun 25. Ann Hematol. 2019. PMID: 31240471 Clinical Trial.
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.
Shallis RM, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukhereje S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Shallis RM, et al. Leuk Lymphoma. 2020 May;61(5):1220-1225. doi: 10.1080/10428194.2020.1728753. Epub 2020 Feb 26. Leuk Lymphoma. 2020. PMID: 32100599 Free PMC article. No abstract available.
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Stahl M, et al. Leukemia. 2020 Dec;34(12):3149-3160. doi: 10.1038/s41375-020-0783-3. Epub 2020 Mar 4. Leukemia. 2020. PMID: 32132655 Free PMC article.
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Martínez-Cuadrón D, Serrano J, Gil C, Tormo M, Martínez-Sánchez P, Pérez-Simón JA, García-Boyero R, Rodríguez-Medina C, López-Pavía M, Benavente C, Bergua J, Lavilla-Rubira E, Amigo ML, Herrera P, Alonso-Domínguez JM, Bernal T, Colorado M, Sayas MJ, Algarra L, Vidriales MB, Rodríguez-Macías G, Vives S, Pérez-Encinas MM, López A, Noriega V, García-Fortes M, Ramos F, Rodríguez-Gutiérrez JI, Costilla-Barriga L, Labrador J, Boluda B, Rodríguez-Veiga R, Martínez-López J, Sanz MA, Montesinos P. Martínez-Cuadrón D, et al. Leukemia. 2021 Jun;35(6):1571-1585. doi: 10.1038/s41375-020-01058-4. Epub 2020 Oct 19. Leukemia. 2021. PMID: 33077867
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study.
Rodríguez-Arbolí E, Martínez-Cuadrón D, Rodríguez-Veiga R, Carrillo-Cruz E, Gil-Cortés C, Serrano-López J, Bernal Del Castillo T, Martínez-Sánchez MDP, Rodríguez-Medina C, Vidriales B, Bergua JM, Benavente C, García-Boyero R, Herrera-Puente P, Algarra L, Sayas-Lloris MJ, Fernández R, Labrador J, Lavilla-Rubira E, Barrios-García M, Tormo M, Serrano-Maestro A, Sossa-Melo CL, García-Belmonte D, Vives S, Rodríguez-Gutiérrez JI, Albo-López C, Garrastazul-Sánchez MP, Colorado-Araujo M, Mariz J, Sanz MÁ, Pérez-Simón JA, Montesinos P; PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular) Cooperative Groups. Rodríguez-Arbolí E, et al. Transplant Cell Ther. 2021 Apr;27(4):311.e1-311.e10. doi: 10.1016/j.jtct.2020.12.029. Epub 2021 Jan 8. Transplant Cell Ther. 2021. PMID: 33836871 Free article.
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda B, Solana-Altabella A, Cano I, Acuña-Cruz E, Rodríguez-Veiga R, Ballesta-López O, Megías-Vericat JE, Martínez-Cuadrón D, Gómez I, Solves P, Lorenzo I, Piñana JL, Sanz J, Guerreiro M, Montoro Gómez J, Díaz-González A, Marco J, Blanco A, Sanz MÁ, Montesinos P. Boluda B, et al. J Clin Apher. 2021 Aug;36(4):612-620. doi: 10.1002/jca.21901. Epub 2021 May 8. J Clin Apher. 2021. PMID: 33964038 Free PMC article.
50 results